(Q2)Apr 30, 2024 | (Q1)Jan 31, 2024 | (Q3)Jul 31, 2023 | (Q2)Apr 30, 2023 | (Q1)Jan 31, 2023 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | |||||
Gross profit | |||||
Operating expense | 176.12%173K | -64.78%18.4K | 16.03K | 62.65K | 52.23K |
Selling and administrative expenses | 367.38%58.3K | -41.32%13.48K | --13.49K | --12.47K | --22.98K |
-Selling and marketing expense | --22.04K | ---- | ---- | --0 | ---- |
-General and administrative expense | 190.69%36.26K | -41.32%13.48K | --13.49K | --12.47K | --22.98K |
Other operating expenses | 128.58%114.7K | -83.20%4.92K | --2.53K | --50.18K | --29.25K |
Operating profit | -176.12%-173K | 64.78%-18.4K | -16.03K | -62.65K | -52.23K |
Net non-operating interest income (expenses) | |||||
Other net income (expenses) | |||||
Income before tax | -176.12%-173K | 64.78%-18.4K | -16.03K | -62.65K | -52.23K |
Income tax | |||||
Earnings from equity interest net of tax | |||||
Net income | -176.12%-173K | 64.78%-18.4K | -16.03K | -62.65K | -52.23K |
Net income continuous operations | -176.12%-173K | 64.78%-18.4K | ---16.03K | ---62.65K | ---52.23K |
Noncontrolling interests | |||||
Net income attributable to the company | -176.12%-173K | 64.78%-18.4K | -16.03K | -62.65K | -52.23K |
Preferred stock dividends | |||||
Other under preferred stock dividend | |||||
Net income attributable to common stockholders | -176.12%-173K | 64.78%-18.4K | -16.03K | -62.65K | -52.23K |
Diluted earnings per share | -223.83%-0.01 | 65.13%-0.0009 | -0.0008 | -0.0031 | -0.0026 |
Basic earnings per share | -223.83%-0.01 | 65.13%-0.0009 | -0.0008 | -0.0031 | -0.0026 |
Dividend per share | |||||
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.